AACR-话题@MedSci

#AACR#

120篇内容 | 3135人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1552001, encodeId=b3ef155200180, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020：Durvalumab治疗III期不可切除NSCLC的吸烟状态亚组分析, objectType=article, longId=193155, objectId=a1ad1931551a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1ad1931551a, replyNumber=0, likeNumber=64, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1ad1931551a, moduleTitle=AACR 2020：Durvalumab治疗III期不可切除NSCLC的吸烟状态亚组分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1ad1931551a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552000, encodeId=275b1552000c8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020：STK11和KEAP1突变影响K药一线治疗PDL1阳性患者（Keynote 042研究）, objectType=article, longId=193109, objectId=bc64193109cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc64193109cc, replyNumber=0, likeNumber=78, createdTime=2020-04-30, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc64193109cc, moduleTitle=AACR 2020：STK11和KEAP1突变影响K药一线治疗PDL1阳性患者（Keynote 042研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc64193109cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551999, encodeId=06a81551999b4, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020：豪森药业阿美替尼用于EGFR突变耐药的NSCLC患者结果公布, objectType=article, longId=193108, objectId=28561931082d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28561931082d, replyNumber=0, likeNumber=78, createdTime=2020-04-30, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28561931082d, moduleTitle=AACR 2020：豪森药业阿美替尼用于EGFR突变耐药的NSCLC患者结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28561931082d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551998, encodeId=8ad4155199854, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020：大样本NSCLC中的FGFR基因突变结果发布, objectType=article, longId=193107, objectId=ee7719310e83, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee7719310e83, replyNumber=0, likeNumber=65, createdTime=2020-04-30, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee7719310e83, moduleTitle=AACR 2020：大样本NSCLC中的FGFR基因突变结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee7719310e83)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551997, encodeId=e1ec155199e49, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究, objectType=article, longId=193104, objectId=5d7319310411, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d7319310411, replyNumber=0, likeNumber=65, createdTime=2020-04-30, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d7319310411, moduleTitle=AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d7319310411)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551996, encodeId=32e31551996f7, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=2019 AACR：MultiTAA T细胞疗法治疗胰腺癌, objectType=article, longId=175928, objectId=1b861e592863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b861e592863, replyNumber=0, likeNumber=63, createdTime=2019-07-24, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b861e592863, moduleTitle=2019 AACR：MultiTAA T细胞疗法治疗胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b861e592863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551995, encodeId=dafa155199510, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR：恩替司他与PD-1单抗Keytruda联合是抗PD1治疗失败后晚期黑色素瘤的有效选择, objectType=article, longId=163748, objectId=4e6a163e4806, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e6a163e4806, replyNumber=0, likeNumber=64, createdTime=2019-04-08, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e6a163e4806, moduleTitle=AACR：恩替司他与PD-1单抗Keytruda联合是抗PD1治疗失败后晚期黑色素瘤的有效选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e6a163e4806)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551994, encodeId=de4d155199480, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR：PD-1单抗keytruda在晚期小细胞肺癌患者中显示出抗肿瘤潜力, objectType=article, longId=163662, objectId=fc6a1636624d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc6a1636624d, replyNumber=0, likeNumber=98, createdTime=2019-04-06, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc6a1636624d, moduleTitle=AACR：PD-1单抗keytruda在晚期小细胞肺癌患者中显示出抗肿瘤潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc6a1636624d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551993, encodeId=1881155199306, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR19：JTX-8064能够激活肿瘤微环境中的巨噬细胞, objectType=article, longId=163660, objectId=23fe163660df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23fe163660df, replyNumber=0, likeNumber=0, createdTime=2019-04-06, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23fe163660df, moduleTitle=AACR19：JTX-8064能够激活肿瘤微环境中的巨噬细胞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23fe163660df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551992, encodeId=516c15519925b, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR19：Actimab-A和Venetoclax具有协同作用, objectType=article, longId=163659, objectId=46c716365928, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46c716365928, replyNumber=0, likeNumber=59, createdTime=2019-04-06, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46c716365928, moduleTitle=AACR19：Actimab-A和Venetoclax具有协同作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46c716365928)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551991, encodeId=03a8155199121, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR19：安斯泰来的Xospata在急性髓性白血病研究中提高了整体存活率, objectType=article, longId=163460, objectId=c303163460a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c303163460a8, replyNumber=0, likeNumber=62, createdTime=2019-04-04, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c303163460a8, moduleTitle=AACR19：安斯泰来的Xospata在急性髓性白血病研究中提高了整体存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c303163460a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551990, encodeId=528a1551990d3, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR19：APX005M具有治疗转移性胰腺癌的前景, objectType=article, longId=163457, objectId=c1ec16345ee8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1ec16345ee8, replyNumber=0, likeNumber=89, createdTime=2019-04-04, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1ec16345ee8, moduleTitle=AACR19：APX005M具有治疗转移性胰腺癌的前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1ec16345ee8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551989, encodeId=950a155198916, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％, objectType=article, longId=163455, objectId=500616345538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=500616345538, replyNumber=0, likeNumber=68, createdTime=2019-04-04, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=500616345538, moduleTitle=AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=500616345538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551988, encodeId=44ca1551988ce, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=2019年AACR年会：Tolero将展示TP-0903和TP-0184的全新数据, objectType=article, longId=161434, objectId=0d9d161434e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d9d161434e3, replyNumber=0, likeNumber=51, createdTime=2019-03-02, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d9d161434e3, moduleTitle=2019年AACR年会：Tolero将展示TP-0903和TP-0184的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d9d161434e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551987, encodeId=27ba155198e68, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=2019年AACR年会：Syros将展示选择性CDK7抑制剂SY-1365的全新临床前数据, objectType=article, longId=161433, objectId=0c111614338f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c111614338f, replyNumber=0, likeNumber=86, createdTime=2019-03-02, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c111614338f, moduleTitle=2019年AACR年会：Syros将展示选择性CDK7抑制剂SY-1365的全新临床前数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c111614338f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551986, encodeId=495e1551986be, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=ArQule在第30届EORTC / AACR / NCI研讨会上介绍了ARQ 751的全新数据, objectType=article, longId=153907, objectId=c34115390e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c34115390e7b, replyNumber=0, likeNumber=77, createdTime=2018-11-21, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c34115390e7b, moduleTitle=ArQule在第30届EORTC / AACR / NCI研讨会上介绍了ARQ 751的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c34115390e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551985, encodeId=bf6115519859c, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2018：主会议发言首位华人女科学家刘小乐：大数据挖掘在肿瘤免疫治疗中的关键作用, objectType=article, longId=136808, objectId=bf8a13680802, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf8a13680802, replyNumber=0, likeNumber=82, createdTime=2018-04-30, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf8a13680802, moduleTitle=AACR 2018：主会议发言首位华人女科学家刘小乐：大数据挖掘在肿瘤免疫治疗中的关键作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf8a13680802)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551984, encodeId=52b015519847a, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=美国癌症研究协会（AACR）表观遗传学会议：Rigosertib联合阿扎胞苷, objectType=article, longId=131565, objectId=f6031315654c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6031315654c, replyNumber=0, likeNumber=75, createdTime=2018-03-07, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6031315654c, moduleTitle=美国癌症研究协会（AACR）表观遗传学会议：Rigosertib联合阿扎胞苷, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6031315654c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551983, encodeId=f8cd155198337, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2017：肿瘤免疫治疗全新猛料! Opdivo一线治疗NSCLC或将重获转机（CheckMate 026）, objectType=article, longId=95184, objectId=6b1595184c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b1595184c3, replyNumber=0, likeNumber=70, createdTime=2017-04-10, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b1595184c3, moduleTitle=AACR 2017：肿瘤免疫治疗全新猛料! Opdivo一线治疗NSCLC或将重获转机（CheckMate 026）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b1595184c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551982, encodeId=a03f155198241, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR年会报告：乳腺癌并不可怕！可怕的是助纣为虐的脂肪！, objectType=article, longId=94646, objectId=b97694646f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b97694646f8, replyNumber=0, likeNumber=50, createdTime=2017-04-06, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b97694646f8, moduleTitle=AACR年会报告：乳腺癌并不可怕！可怕的是助纣为虐的脂肪！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b97694646f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

AACR

2020-05-29

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2020：Durvalumab治疗III期不可切除NSCLC的吸烟状态亚组分析

2020-05-01

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2020：STK11和KEAP1突变影响K药一线治疗PDL1阳性患者（Keynote 042研究）

2020-04-30

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2020：豪森药业阿美替尼用于EGFR突变耐药的NSCLC患者结果公布

2020-04-30

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2020：大样本NSCLC中的FGFR基因突变结果发布

2020-04-30

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究

2020-04-30

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

2019 AACR：MultiTAA T细胞疗法治疗胰腺癌

2019-07-24

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR：恩替司他与PD-1单抗Keytruda联合是抗PD1治疗失败后晚期黑色素瘤的有效选择

2019-04-08

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR：PD-1单抗keytruda在晚期小细胞肺癌患者中显示出抗肿瘤潜力

2019-04-06

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR19：JTX-8064能够激活肿瘤微环境中的巨噬细胞

2019-04-06

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR19：Actimab-A和Venetoclax具有协同作用

2019-04-06

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR19：安斯泰来的Xospata在急性髓性白血病研究中提高了整体存活率

2019-04-04

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR19：APX005M具有治疗转移性胰腺癌的前景

2019-04-04

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％

2019-04-04

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

2019年AACR年会：Tolero将展示TP-0903和TP-0184的全新数据

2019-03-02

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

2019年AACR年会：Syros将展示选择性CDK7抑制剂SY-1365的全新临床前数据

2019-03-02

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

ArQule在第30届EORTC / AACR / NCI研讨会上介绍了ARQ 751的全新数据

2018-11-21

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2018：主会议发言首位华人女科学家刘小乐：大数据挖掘在肿瘤免疫治疗中的关键作用

2018-04-30

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

美国癌症研究协会（AACR）表观遗传学会议：Rigosertib联合阿扎胞苷

2018-03-07

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR 2017：肿瘤免疫治疗全新猛料! Opdivo一线治疗NSCLC或将重获转机（CheckMate 026）

2017-04-10

Luyuxie_14 (审核中...)

前往app查看评论内容

#AACR#

AACR年会报告：乳腺癌并不可怕！可怕的是助纣为虐的脂肪！

2017-04-06

科室
- - 订阅+
  - 更多科室
工具
服务